WallStSmart

POET Technologies Inc (POET)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 23986% more annual revenue ($258.90M vs $1.07M). POET leads profitability with a 0.0% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

POET

Avoid

24

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 4.0Quality: 6.5
Piotroski: 4/9Altman Z: -8.03

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

POETSignificantly Overvalued (-57.1%)

Margin of Safety

-57.1%

Fair Value

$3.71

Current Price

$7.12

$3.41 premium

UndervaluedFair: $3.71Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

POET2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
1075.0%10/10

Revenue surging 1075.0% year-over-year

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

POET4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.23B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-61.6%2/10

ROE of -61.6% — below average capital efficiency

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : POET

The strongest argument for POET centers on Revenue Growth, Debt/Equity. Revenue growth of 1075.0% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : POET

The primary concerns for POET are EPS Growth, Market Cap, Profit Margin.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

POET is growing revenue faster at 1075.0% — sustainability is the question.

Monitor SEMICONDUCTORS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 24/100) and 43.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

POET Technologies Inc

TECHNOLOGY · SEMICONDUCTORS · USA

POET Technologies Inc. is a cutting-edge semiconductor company specializing in its proprietary Opto-Electronic Integrated Circuit (OEIC) platform, which uniquely integrates optical and electronic functionalities to enhance data transmission capabilities. Targeting high-growth sectors such as datacenters, telecommunications, and the automotive industry, POET is focused on delivering solutions that significantly boost data speeds while minimizing power consumption. With an unwavering commitment to research and development, the company is well-positioned to leverage emerging opportunities in the optoelectronics sector, thereby addressing critical industry demands and driving the future of technological innovation.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?